Effect of the Dysbindin Gene on Antimanic Agents in Patients with Bipolar I Disorder.
- Author:
Dong Hwan YUN
1
;
Chi Un PAE
;
Antonio DRAGO
;
Laura MANDELLI
;
Diana DE RONCHI
;
Ashwin A PATKAR
;
In Ho PAIK
;
Alessandro SERRETTI
;
Jung Jin KIM
Author Information
- Publication Type:Original Article
- Keywords: Pharmacogenetics; Dysbindin; Bipolar disorder; Antimanic agents
- MeSH: Antimanic Agents*; Bipolar Disorder; Humans; Pharmacogenetics; Valproic Acid
- From:Psychiatry Investigation 2008;5(2):102-105
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVE: We previously reported an association between dysbindin gene (DTNBP1) variants and bipolar I disorder (BID). This paper expands upon previous findings suggesting that DTNBP1 variants may play a role in the response to acute mood stabilizer treatment. METHODS: A total of 45 BID patients were treated with antimanic agents (lithium, valproate, or carbamazepine) for an average of 36.52 (+/-19.87) days. After treatment, the patients were evaluated using the Clinical Global Impression (CGI) scale and the Young Mania Rating Scale (YMRS) and genotyped for their DTNBP1 variants (rs3213207 A/G, rs1011313 C/T, rs2005976 G/A, rs760761 C/T and rs2619522 A/C). RESULTS: There was no association between the variants investigated and response to mood stabilizer treatment, even after considering possible stratification factors. CONCLUSION: Although the small number of subjects is an important limitation in our study, DTNBP1 does not seem to be involved in acute antimanic efficacy.
